Literature DB >> 8014494

Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: synergy with fluconazole for killing.

E Brummer1, D A Stevens.   

Abstract

Enhancement of anticryptococcal activity in macrophages by macrophage colony-stimulating factor (M-CSF) and possible synergy between macrophages and fluconazole for killing of Cryptococcus neoformans were tested. M-CSF (48 h)-treated macrophages underwent dramatic morphologic changes and inhibited cryptococcal multiplication by 96% +/- 4%, which was greater (P < .001) than that of macrophages cultured in medium alone. M-CSF (5000 units/mL) induced optimal anticryptococcal activity but did not increase percentage of phagocytosis. NG-mono-methyl-L-arginine did not affect enhanced fungistatic activity. For a very fluconazole-sensitive isolate, fungistatic macrophages synergized with fungistatic doses of fluconazole for killing; for a less sensitive isolate, synergy was significant only when macrophages were activated with M-CSF or interferon-gamma plus lipopolysaccharide; for a fluconazole-resistant isolate, macrophages collaborated with fluconazole for additive fungistasis but not killing, and M-CSF-treated macrophages were significantly more fungistatic with fluconazole than were nonactivated macrophages.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8014494     DOI: 10.1093/infdis/170.1.173

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Trends in immunotherapy of fungal infections.

Authors:  B J Kullberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

3.  Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice.

Authors:  K V Clemons; J E Lutz; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 4.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

5.  Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity.

Authors:  F Nassar; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

6.  Effect of macrophage colony-stimulating factor on anticryptococcal activity of bronchoalveolar macrophages: synergy with fluconazole for killing.

Authors:  E Brummer; F Nassar; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

7.  Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.

Authors:  J Mukherjee; M Feldmesser; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

8.  Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans.

Authors:  Shichina Kannambath; Joseph N Jarvis; Rachel M Wake; Nicky Longley; Angela Loyse; Vicky Matzaraki; Raúl Aguirre-Gamboa; Cisca Wijmenga; Ronan Doyle; Maria Paximadis; Caroline T Tiemessen; Vinod Kumar; Alan Pittman; Graeme Meintjes; Thomas S Harrison; Mihai G Netea; Tihana Bicanic
Journal:  Open Forum Infect Dis       Date:  2020-10-16       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.